Latest Insider Transactions at Verona Pharma PLC (VRNA)
This section provides a real-time view of insider transactions for Verona Pharma PLC (VRNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verona Pharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verona Pharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 21
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
116,696
-0.83%
|
$466,784
$4.38 P/Share
|
|
Oct 21
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
110,456
-0.74%
|
$441,824
$4.38 P/Share
|
|
Oct 18
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
249,728
-1.74%
|
$998,912
$4.38 P/Share
|
|
Oct 18
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
245,784
-1.61%
|
$983,136
$4.38 P/Share
|
|
Sep 11
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
600,000
-4.02%
|
$1,800,000
$3.76 P/Share
|
|
Sep 11
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
600,000
-3.79%
|
$1,800,000
$3.76 P/Share
|
|
Aug 13
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
398,400
-1.3%
|
$1,195,200
$3.23 P/Share
|
|
Aug 13
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
398,400
-1.23%
|
$1,195,200
$3.23 P/Share
|
|
Aug 12
2024
|
David R Ebsworth Director |
BUY
Open market or private purchase
|
Direct |
36,000
+3.93%
|
$72,000
$2.87 P/Share
|
|
Aug 12
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,600
-0.01%
|
$4,800
$3.13 P/Share
|
|
Aug 12
2024
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
1,600
-0.01%
|
$4,800
$3.13 P/Share
|
|
Aug 07
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
314,800
-2.01%
|
$629,600
$2.62 P/Share
|
|
Aug 07
2024
|
Mark W Hahn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+4.86%
|
-
|
|
Aug 07
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
87,904
-3.24%
|
$175,808
$2.62 P/Share
|
|
Aug 07
2024
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+6.86%
|
-
|
|
Aug 07
2024
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
314,800
-1.9%
|
$629,600
$2.62 P/Share
|
|
Aug 07
2024
|
David Zaccardelli President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+4.61%
|
-
|
|
Aug 01
2024
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
88,544
-0.56%
|
$177,088
$2.83 P/Share
|
|
Aug 01
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
88,544
-0.59%
|
$177,088
$2.83 P/Share
|
|
Aug 01
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
106,232
-4.05%
|
$212,464
$2.83 P/Share
|
|
May 03
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
36,248
-1.36%
|
$36,248
$1.96 P/Share
|
|
May 01
2024
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
88,544
-0.56%
|
$88,544
$1.93 P/Share
|
|
May 01
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
73,824
-2.7%
|
$73,824
$1.93 P/Share
|
|
May 01
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
88,544
-0.59%
|
$88,544
$1.93 P/Share
|
|
Feb 05
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
36,248
-1.31%
|
$72,496
$2.22 P/Share
|
|
Feb 01
2024
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
480,664
-3.1%
|
$961,328
$2.29 P/Share
|
|
Feb 01
2024
|
Claire Poll General Counsel |
BUY
Bona fide gift
|
Indirect |
116,592
+9.01%
|
-
|
|
Feb 01
2024
|
Claire Poll General Counsel |
SELL
Bona fide gift
|
Direct |
116,592
-6.7%
|
-
|
|
Feb 01
2024
|
Claire Poll General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
103,408
-5.61%
|
$206,816
$2.29 P/Share
|
|
Feb 01
2024
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
72,768
-2.56%
|
$145,536
$2.29 P/Share
|
|
Feb 01
2024
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
480,200
-2.92%
|
$960,400
$2.29 P/Share
|
|
Nov 20
2023
|
Martin Edwards Director |
BUY
Open market or private purchase
|
Direct |
33,736
+18.9%
|
$33,736
$1.84 P/Share
|
|
Nov 06
2023
|
David R Ebsworth Director |
BUY
Open market or private purchase
|
Direct |
160,000
+15.93%
|
$160,000
$1.98 P/Share
|
|
Nov 03
2023
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,752
-2.03%
|
$58,752
$1.92 P/Share
|
|
Nov 01
2023
|
Claire Poll General Counsel |
BUY
Bona fide gift
|
Indirect |
196,096
+15.61%
|
-
|
|
Nov 01
2023
|
Claire Poll General Counsel |
SELL
Bona fide gift
|
Direct |
196,096
-10.64%
|
-
|
|
Nov 01
2023
|
Claire Poll General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
173,904
-8.62%
|
$173,904
$1.74 P/Share
|
|
Nov 01
2023
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173,136
-5.64%
|
$173,136
$1.74 P/Share
|
|
Nov 01
2023
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
809,008
-4.96%
|
$809,008
$1.74 P/Share
|
|
Nov 01
2023
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
809,008
-4.69%
|
$809,008
$1.74 P/Share
|
|
Oct 20
2023
|
Mark W Hahn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+4.67%
|
-
|
|
Oct 20
2023
|
Claire Poll General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+9.02%
|
-
|
|
Oct 20
2023
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+6.11%
|
-
|
|
Oct 20
2023
|
David Zaccardelli President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+4.44%
|
-
|
|
Aug 07
2023
|
Claire Poll General Counsel |
BUY
Bona fide gift
|
Indirect |
89,976
+9.43%
|
-
|
|
Aug 07
2023
|
Claire Poll General Counsel |
SELL
Bona fide gift
|
Direct |
89,976
-4.72%
|
-
|
|
Aug 07
2023
|
Claire Poll General Counsel |
SELL
Open market or private sale
|
Direct |
1,512
-0.08%
|
$3,024
$2.47 P/Share
|
|
Aug 07
2023
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,616
-0.06%
|
$17,232
$2.47 P/Share
|
|
Aug 07
2023
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
8,616
-0.05%
|
$17,232
$2.47 P/Share
|
|
Aug 07
2023
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,600
-0.06%
|
$3,200
$2.47 P/Share
|